Pharmacyclics, Inc., a pharmaceutical company, is developing drugs to treat cancer and other diseases. Its pharmaceutical agents are synthetic small molecules designed to target key biochemical pathways in diseased cells. The company’s principal development products include Xcytrin injection, an anti-cancer agent that is in phase II clinical trials; and Histone Deacetylase Inhibitor, a phase I clinical trial product that targets histone deacetylase enzymes and inhibits their function. Its other development products comprise HDAC-8 selective inhibitor, a preclinical stage drug for the treatment of cancer; a small molecule inhibitor of Factor VIIa, which has demonstrated...